Biotech Plot Twist: Sage Gets a New Home

Here’s a coffee break scoop: Sage Therapeutics, once a biotech darling, just got snapped up by Supernus for up to $795M—way more than Biogen’s earlier lowball offer. After a rollercoaster ride (think: stock price nosedives and legal drama), Sage’s postpartum depression drug is now Supernus’ ticket to a bigger medicine cabinet. For everyday investors, it’s a reminder that sometimes, holding out for a better deal pays off—even if the story doesn’t end with fireworks. #BiotechNews #Investing #Acquisition #Business #EntrepreneurshipStartup